Summary
BioCardia Inc (BioCardia) is a regenerative medicine company that develops cellular and cell-derived therapeutics aimed at treating unmet cardiovascular and pulmonary diseases. The company's pipeline products include CardiAMP, CardiALLO, and PulmALLO. Its products are designed for patients suffering from conditions such as ischemic heart failure and acute respiratory distress syndrome. BioCardia's therapies are utilized in the healthcare industry, specifically targeting medical professionals and institutions involved in cardiovascular and pulmonary care. BioCardia is headquartered in San Carlos, California, the US.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioCardia Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- BioCardia Inc Company Overview
- BioCardia Inc Company Snapshot
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc - Pipeline Analysis Overview
- BioCardia Inc - Key Facts
- BioCardia Inc - Major Products and Services
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Pipeline Products Overview
- CardiALLO - Heart Failure
- CardiALLO - Heart Failure Product Overview
- CardiALLO - Heart Failure Clinical Trial
- CardiAMP - Chronic Myocardial Ischemia
- CardiAMP - Chronic Myocardial Ischemia Product Overview
- CardiAMP - Chronic Myocardial Ischemia Clinical Trial
- CardiAMP - Heart Failure
- CardiAMP - Heart Failure Product Overview
- CardiAMP - Heart Failure Clinical Trial
- CardiAMP - Post Acute Infarction
- CardiAMP - Post Acute Infarction Product Overview
- Fusion Imaging System
- Fusion Imaging System Product Overview
- Helix Transendocardial Delivery System
- Helix Transendocardial Delivery System Product Overview
- Helix Transendocardial Delivery System Clinical Trial
- BioCardia Inc - Key Competitors
- BioCardia Inc - Key Employees
- BioCardia Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- BioCardia Inc, Recent Developments
- Aug 24, 2026: Biocardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-on de Novo Pre-Submission for Approval
- Apr 28, 2026: Biocardia Announces Allowance of Japanese Patent on Proprietary Heart3D Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
- Apr 02, 2026: BioCardia Files Request for Meeting with FDA to Discuss Accelerated Approval Pathway for CardiAMP System in Ischemic Heart Failure
- Mar 17, 2026: Biocardia Announces Pre-submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA
- Mar 03, 2026: Biocardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
- Feb 10, 2026: Biocardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
- Feb 03, 2026: Biocardia Announces Late Breaking Echocardiography Results From the CardiAMP HF Trial To Be Presented at Technology and Heart Failure Therapeutics (THT)
- Dec 16, 2025: BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
- Oct 30, 2025: BioCardia Announces First Patient Enrollment in Phase 3 CardiAMP HF II Trial at University of Wisconsin
- Sep 22, 2025: BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
- Appendix
- Methodology
- About the Analyst
- Contact Us
- Disclaimer
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Indication
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc, Key Facts
- BioCardia Inc, Major Products and Services
- BioCardia Inc Number of Pipeline Products by Development Stage
- BioCardia Inc Pipeline Products Summary by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Ongoing Clinical Trials Summary
- CardiALLO - Heart Failure - Product Status
- CardiALLO - Heart Failure - Product Description
- CardiALLO - Heart Failure - Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (hMSCs) in Patients With Ischemic Heart Failure With Reduced Ejection Fraction (HFrEF)
- CardiAMP - Chronic Myocardial Ischemia - Product Status
- CardiAMP - Chronic Myocardial Ischemia - Product Description
- CardiAMP - Chronic Myocardial Ischemia - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients with Refractory Angina Pectoris and Chronic Myocardial Ischemia: CardiAMP CMI Trial
- CardiAMP - Heart Failure - Product Status
- CardiAMP - Heart Failure - Product Description
- CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure II Trial
- CardiAMP - Post Acute Infarction - Product Status
- CardiAMP - Post Acute Infarction - Product Description
- Fusion Imaging System - Product Status
- Fusion Imaging System - Product Description
- Helix Transendocardial Delivery System - Product Status
- Helix Transendocardial Delivery System - Product Description
- Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care
- Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
- BioCardia Inc, Key Employees
- BioCardia Inc, Subsidiaries
- Glossary
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioDelivery Sciences International Inc
- Cypherpunk Technologies Inc
- Sentynl Therapeutics Inc
- Juventas Therapeutics Inc
- DiscGenics Inc
